tetano
Editor, Senior Moderator
Arch Clin Neuropsychol
. 2022 Dec 2;acac093.
doi: 10.1093/arclin/acac093. Online ahead of print.
Cognitive Complaints Assessment and Neuropsychiatric Disorders After Mild COVID-19 Infection
Mariana Beiral Hammerle[SUP] 1 [/SUP], Deborah Santos Sales[SUP] 1 [/SUP], Patricia Gomes Pinheiro[SUP] 1 [/SUP], Elisa Gutman Gouvea[SUP] 1 [/SUP], Pedro Ignacio F M de Almeida[SUP] 1 [/SUP], Clarissa de Araujo Davico[SUP] 1 [/SUP], Rayanne S Souza[SUP] 1 [/SUP], Carina Tellaroli Spedo[SUP] 2 [/SUP], Denise Hack Nicaretta[SUP] 1 [/SUP], Regina Maria Papais Alvarenga[SUP] 1 [/SUP], Karina Lebeis Pires[SUP] 1 [/SUP], Luiz Claudio Santos Thuler[SUP] 3 [/SUP], Claudia Cristina Ferreira Vasconcelos[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: This study aimed to analyze cognitive impairment associated with long-term coronavirus disease 2019 (COVID-19) syndrome and its correlation with anxiety, depression, and fatigue in patients infected with severe acute respiratory syndrome coronavirus.
Methods: This was a cross-sectional study of 127 patients with COVID-19. Tests to screen for neuropsychiatric symptoms included the Fatigue Severity Scale, Mini-Mental State Exam 2 (MMSE-2), Symbol Digit Modalities Test (SDMT), and Hospital Anxiety and Depression Scale.
Results: In cognitive tests, SDMT was abnormal in 22%, being more sensitive than MMSE-2 to detect cognitive changes. Furthermore, although manifestations such as fatigue, depression, and anxiety were frequent in the post-COVID-19 phase, these 3 conditions, known to contribute to cognitive impairment, were slightly correlated with worse performance on the rapid screening tests.
Conclusions: In patients with mild COVID-19 and cognitive complaints, SDMT helped to confirm disturbances in the attention domain and processing speed.
Keywords: COVID-19; Neurocognitive deficits; Neurocognitive screenings; Post-COVID-19.
. 2022 Dec 2;acac093.
doi: 10.1093/arclin/acac093. Online ahead of print.
Cognitive Complaints Assessment and Neuropsychiatric Disorders After Mild COVID-19 Infection
Mariana Beiral Hammerle[SUP] 1 [/SUP], Deborah Santos Sales[SUP] 1 [/SUP], Patricia Gomes Pinheiro[SUP] 1 [/SUP], Elisa Gutman Gouvea[SUP] 1 [/SUP], Pedro Ignacio F M de Almeida[SUP] 1 [/SUP], Clarissa de Araujo Davico[SUP] 1 [/SUP], Rayanne S Souza[SUP] 1 [/SUP], Carina Tellaroli Spedo[SUP] 2 [/SUP], Denise Hack Nicaretta[SUP] 1 [/SUP], Regina Maria Papais Alvarenga[SUP] 1 [/SUP], Karina Lebeis Pires[SUP] 1 [/SUP], Luiz Claudio Santos Thuler[SUP] 3 [/SUP], Claudia Cristina Ferreira Vasconcelos[SUP] 1 [/SUP]
Affiliations
- PMID: 36464245
- DOI: 10.1093/arclin/acac093
Abstract
Objectives: This study aimed to analyze cognitive impairment associated with long-term coronavirus disease 2019 (COVID-19) syndrome and its correlation with anxiety, depression, and fatigue in patients infected with severe acute respiratory syndrome coronavirus.
Methods: This was a cross-sectional study of 127 patients with COVID-19. Tests to screen for neuropsychiatric symptoms included the Fatigue Severity Scale, Mini-Mental State Exam 2 (MMSE-2), Symbol Digit Modalities Test (SDMT), and Hospital Anxiety and Depression Scale.
Results: In cognitive tests, SDMT was abnormal in 22%, being more sensitive than MMSE-2 to detect cognitive changes. Furthermore, although manifestations such as fatigue, depression, and anxiety were frequent in the post-COVID-19 phase, these 3 conditions, known to contribute to cognitive impairment, were slightly correlated with worse performance on the rapid screening tests.
Conclusions: In patients with mild COVID-19 and cognitive complaints, SDMT helped to confirm disturbances in the attention domain and processing speed.
Keywords: COVID-19; Neurocognitive deficits; Neurocognitive screenings; Post-COVID-19.